Abstracts tagged "Randomized Trial"

Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: LB10 • ACR Convergence 2025
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Eric F. Morand¹, Cristina Arriens², Marilyn Pike³, Joan Merrill⁴, Victoria Werth⁵, Zahi Touma⁶, Razvan C. Ionitescu⁷, Masato Okada⁸, Ilias Kouris⁹, Yogita Kolekar¹⁰, Junyu Nie¹⁰, Venkat Renukuntla¹⁰, Thomas Wegman¹⁰ and Ronald van Vollenhoven¹¹, ¹Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Rheumatology, MedPharm Consulting, Inc, Bethesda, ⁴Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, ⁵University of Pennsylvania, Merion Station, Pennsylvania, ⁶University of Toronto, Toronto, Ontario, Canada, ⁷Medart Cliniq, Department of Rheumatology, Râmnicu Vâlcea, Romania, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Eli Lilly and Company Global, Basingstoke, United Kingdom, ¹⁰Bristol Myers Squibb, Princeton, ¹¹Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: There is a substantial unmet need for effective, well-tolerated therapies for patients with SLE. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: LB20 • ACR Convergence 2025
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Désirée van der Heijde¹, Philip Mease², Carle Paul³, Frank Behrens⁴, Laure Gossec⁵, Yuko Kaneko⁶, Lihi Eder⁷, Laura Coates⁸, Andrew Pink⁹, Weiguo Wan¹⁰, Enrique Soriano¹¹, Piotr Leszczyński¹², Jose Scher¹³, Atul Deodhar¹⁴, Chahin Pachai¹⁵, Janice Li¹⁶, Xue Fan¹⁶, Sahar Rabbat¹⁶, Caroline Sardinas¹⁷, Michael Plewinski¹⁸, John Vaile¹⁹ and Joseph Merola²⁰, ¹Leiden University Medical Center, Meerssen, Netherlands, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ³Department of Dermatology, INSERM Infinity, Toulouse University, Toulouse, France, ⁴Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁵Sorbonne Université, AP-HP & EULAR, Paris, France, ⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁷University of Toronto, Toronto, Ontario, Canada, ⁸University of Oxford, Oxford, United Kingdom, ⁹St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom, ¹⁰Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Department of Internal Medicine and Metabolic Disorders, Poznań University of Medical Sciences, Poznań, Poland, ¹³New York University School of Medicine, New York, New York, ¹⁴Oregon Health & Science University, Portland, Oregon, ¹⁵Bristol Myers Squibb, Princeton, New Jersey, ¹⁶Bristol Myers Squibb, Princeton, ¹⁷Bristol Myers Squibb, garwood, New Jersey, ¹⁸Bristol Myers Squibb, Green Brook Township, New Jersey, ¹⁹Bristol Myers Squibb, Warren, New Jersey, ²⁰UT Southwestern Medical Center, Dallas, Texas
Background/Purpose: Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor being investigated in active PsA in the global, randomized, double-blind, placebo (PBO)-controlled, phase 3…
Abstract Number: 2368 • ACR Convergence 2025
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease¹, Christopher Ritchlin², Laura Coates³, Alexa P. Kollmeier⁴, Bei Zhou⁵, Yusang Jiang⁵, Karen Bensley⁵, Koeun Im⁶, Rattandeep Batra⁷, Soumya Chakravarty⁸, Proton Rahman⁹ and Désirée Van Der Heijde¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²University of Rochester Medical Center, Canandaigua, NY, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁶Johnson & Johnson, Cambridge, MA, USA, Cambridge, MA, ⁷Johnson & Johnson, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with active psoriatic arthritis (PsA) are at risk of irreversible joint damage that may significantly impact quality of life. Guselkumab (GUS), a fully…
Abstract Number: 1542 • ACR Convergence 2025
Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial
Richard Furie¹, George Bertsias², Lucy Carter³, Eric Morand⁴, Marta Mosca⁵, Marilyn Pike⁶, Vanessa Taieb⁷, Annette Nelde⁸, Ed Vital⁹ and Christian Stach¹⁰, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵University of Pisa, Pisa, Pisa, Italy, ⁶Rheumatology, MedPharm Consulting, Inc., Bethesda, MD, ⁷UCB, Colombes, France, ⁸Biogen, Baar, Switzerland, ⁹University of Leeds, Leeds, England, United Kingdom, ¹⁰UCB, Monheim am Rhein, Germany
Background/Purpose: Despite the evolution of various flare definitions and their inclusion in SLE clinical trials, moderate flares tend to be underestimated in trials owing to…
Abstract Number: 0656 • ACR Convergence 2025
Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Fangfang Sun¹, Huijing Wang¹, Danting Zhang¹, Nan Shen¹, Sheng Chen¹, Tiing Li¹, Weiguo Wan², Shengming Dai³ and Shuang Ye⁴, ¹Renji Hospital, Shanghai, China (People's Republic), ²Huashan Hospital, Shanghai, China (People's Republic), ³Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: B-lymphocyte stimulator was involved in the pathogenesis of SLE. The humanized monoclonal antibody belimumab with 10mg/kg was effective for active patients. The efficacy of…
Abstract Number: 0801 • ACR Convergence 2025
Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
Eric Morand¹, Corine Gaillez², Stephen Oliver³, Swati Ghanshani⁴, Marilia Pozzobon⁵, Weibin Bao⁶ and Ed Vital⁷, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Novartis Pharma AG, Basel, Switzerland, Croissy Sur Seine, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ⁵Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Ianalumab, a fully human monoclonal antibody against the B cell–activating factor receptor (BAFF-R), has a dual mechanism of action of B cell depletion through…
Abstract Number: 2356 • ACR Convergence 2025
Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Joseph F Merola³, Alexis Ogdie⁴, Atul Deodhar⁵, Laura Coates⁶, Stefan Varga⁷, Navya Kalapala⁷, Ying-Ming Jou⁸, Eleni Vritzali⁹ and Laure Gossec¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Princeton, ⁹Bristol Myers Squibb, Boudry, Switzerland, ¹⁰Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: PsA affects male and female patients equally; however, variations in clinical manifestations and treatment responses between sexes have been reported. Deucravacitinib is an oral,…
Abstract Number: 1531 • ACR Convergence 2025
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Ioannis Parodis¹, Julius Lindblom², Roger A. Levy³, Alexander Tsoi¹, Margherita Zen⁴, Dionysis Nikolopoulos⁵, Munther Khamashta⁶, Ryan Tomlinson⁷, Anca Askanase⁸, Ronald van Vollenhoven⁹ and Mandana Nikpour¹⁰, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁴University of Padua, Department of Medicine, Division of Rheumatology, Padua, Italy, ⁵Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁶GSK, Medical Affairs, Dubai, United Arab Emirates, ⁷GSK, Development – R&D, Collegeville, PA, ⁸Columbia University Medical Center, New York, NY, ⁹Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹⁰University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…
Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…
Abstract Number: 0776 • ACR Convergence 2025
Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial
Wolfgang Schmidt¹, Arathi Setty², Christian Dejaco³, Andrea Rubbert-Roth⁴, Maria Cid⁵, Tomonori Ishii⁶, Avani D. Joshi², Nathaniel Zerad², Aditi Kadakia⁷, Shaofei Zhao², Weihan Zhao², Ivan Lagunes², Charles Phillips⁸, Daniel Blockmans⁹ and Peter Merkel¹⁰, ¹Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ²AbbVie Inc, North Chicago, IL, ³Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁴Division of Rheumatology and Immunology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁶Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁷AbbVie Inc, Woburn, MA, ⁸AbbVie Inc, Princeton, NJ, ⁹Department of General Internal Medicine, University Hospitals Leuven; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹⁰University of Pennsylvania, Philadelphia, PA

Background/Purpose: In the SELECT-GCA phase 3 trial, treatment of patients with GCA with upadacitinib 15 mg (UPA15) demonstrated superior rates of disease remission, fewer disease…
Abstract Number: 2357 • ACR Convergence 2025
Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Lihi Eder¹, Iain McInnes², Christopher Ritchlin³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Laura Coates⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Matthew R. Thomas⁹, Eva Cullen⁹, Kristian Reich¹⁰, Joseph F Merola¹¹ and Philip J. Mease¹², ¹University of Toronto, Toronto, ON, Canada, ²University of Glasgow, Glasgow, United Kingdom, ³University of Rochester Medical Center, Canandaigua, NY, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of California, San Diego, School of Medicine, San Diego, CA, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA is a chronic inflammatory disease affecting heterogeneous tissues, with unmet need for therapies with robust efficacy across disease domains. Sonelokimab (SLK) is a…
Abstract Number: 1521 • ACR Convergence 2025
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad Rovin¹, William Pendergraft², Liz Lightstone³, Eric Daugas⁴, Richard Furie⁵, Theodore Omachi², Imran Hassan⁶, Elsa Martins⁷, Thomas Schindler⁷, Jay Garg², Luis Quintana⁸, Piotr Leszczyński⁹ and Ana Malvar¹⁰, ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁴Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Department of Nephrology, Hospital Clinic, Barcelona, Spain, ⁹Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…

1
2
3
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].